Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome

Basit Öğe Kaydı
dc.authoridKaygusuz, Ikbal/0000-0002-5635-505X|Yildirim, Derya/0000-0003-2771-7725;
dc.contributor.authorKarakurt, Feridun
dc.contributor.authorCarlioglu, Ayse
dc.contributor.authorKaygusuz, Ikbal
dc.contributor.authorGumus, Ilknur Inegol
dc.contributor.authorUz, Burak
dc.contributor.authorAkdeniz, Derya
dc.date.accessioned2025-10-24T18:08:48Z
dc.date.available2025-10-24T18:08:48Z
dc.date.issued2014
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractOur study was undertaken to evaluate the levels of asymmetric dimethyl-arginine (ADMA) in a group of patients affected with polycystic ovary syndrome (PCOS)-under ethinyl estradiol-cyproterone acetate treatment or not-as compared with a group of healthy controls. Fifty-eight women with PCOS and 45 patients as control group were included in the study. The 58 women with PCOS were separated into two groups: Group A (n = 29) were treated with an oral contraceptive pill containing 0.035 mg of ethinyl estradiol (EE) and 2 mg of cyproterone acetate (CA) (Diane-35) for 6 months. Group B (n = 29) did not take any drug. Group C (n = 45) was healthy women as control group. Serum levels of ADMA, lipid and glucose metabolism parameters, hormone profile were measured on the sixth month of treatment. ADMA levels were similar in women with PCOS and controls, whereas ADMA levels significantly decreased after a period of 6 months treatment with EE + CA in women with PCOS. ADMA levels and insulin resistance were decreased with treatment. However, patients with PCOS had significantly higher total cholesterol and Low-density lipoprotein cholesterol (LDL-C) compared to controls, treatment with EE + CA did not provide any improvement on lipid parameters. Serum ADMA levels and insulin resistance were lower in PCOS group treated with EE + CA than control group.
dc.identifier.doi10.1007/s00404-013-2960-3
dc.identifier.endpage140
dc.identifier.issn0932-0067
dc.identifier.issn1432-0711
dc.identifier.issue1
dc.identifier.pmid23880889
dc.identifier.scopus2-s2.0-84891874039
dc.identifier.scopusqualityQ2
dc.identifier.startpage135
dc.identifier.urihttps://doi.org/10.1007/s00404-013-2960-3
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3306
dc.identifier.volume289
dc.identifier.wosWOS:000329222100022
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Heidelberg
dc.relation.ispartofArchives Of Gynecology And Obstetrics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectPolycystic ovary syndrome; Asymmetrical dimethyl-arginine; Ethinyl estradiol-cyproterone acetate; Insulin resistance
dc.titleEffect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu